Trial Profile
A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Nevanimibe (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Therapeutic Use
- Sponsors Millendo Therapeutics
- 18 Jul 2020 This trial has been Discontinued in Spain, according to European Clinical Trials Database record.
- 14 Jul 2020 Status changed from recruiting to discontinued.
- 23 Jun 2020 Interim results(n=10) published in Millendo Therapeutics Media Release.